---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-106227"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:39:01.035582+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kymera Q2 net loss $76.6M; cash ~$1B; KT-621 Phase 1 data positive; Gilead CDK2 deal up to $750M

## Summary
- Net loss widened to $76.6M in Q2 2025 ($42.1M Q2 2024); R&D spend rose to $78.4M from $59.2M.
- Cash ~$1B as of July 31, 2025 (including $250M equity offering and Gilead upfront); runway into H2 2028.
- KT-621 Phase 1 healthy volunteer: deep STAT6 degradation, safety undifferentiated from placebo; Phase 1b AD data expected 4Q25; Phase 2b AD/asthma start 4Q25/1Q26.
- Gilead partnership for CDK2 molecular glue: up to $750M total payments including up to $85M upfront/option; Kymera leads research.
- Sanofi to advance KT-485 (IRAK4) into Phase 1 in 2026; $20M preclinical milestone achieved.

## SEC filing metadata
- accession: 0000950170-25-106227
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000095017025106227/0000950170-25-106227-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000095017025106227/kymr-20250811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-106227
- JSON: https://secwatch.observer/filing/0000950170-25-106227.json
- Plain text: https://secwatch.observer/filing/0000950170-25-106227.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.